Victoria Socha

DocwireNews

Among patients with autosomal dominant polycystic kidney disease (ADPKD), a small percentage have no clear family history. This subgroup of patients may face a different clinical course and disease prognosis than those with family history of ADPKD.Vasiliki Gkika and colleagues conducted a study to examine the progression and prognostication of end-stage renal disease (ESRD) in a large cohort of patients with and without a family history of ADPKD. Results were reported at the ERA 59th Congress in a presentation titled Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) Without a Clear Family History Have Rapid Progression and Poor Prognosis.The study included 291 patients who were being followed in a specialized ADPKD outpatient clinic. Patients with and without a clear family history or confirmatory genetic test for ADPKD who had more than ten kidney cysts in a recent magnetic resonance imaging (MRI) scan were included in the study.Total kidney volume was calculated by MRI at study enrollment, and the Mayo Clinic Imagining Category was determined (MCIC). ESRD was defined as future estimated glomerular filtration rate &lt;10 mL/min/1.73 m2 based on the Mayo Clinic Formula that takes into consideration age, total kidney volume, eGFR, sex, race, and MCIC.Of the 291 patients in the overall study cohort, 11.68% (n=34) had no clear family history of ADPKD, and 88.32% (n=257) had a clear family history. The two groups were similar in age, sex, the presence (or not) and age at diagnosis of hypertension, and body mass index. The groups were also similar in age at diagnosis of ADPKD, eGFR, chronic kidney disease stage, and albuminuria.Total kidney volume tended to be higher in the group of patients without a clear family history compared with those with a family history of ADPKD (median, 2210.3 mL vs 1649.9 mL, respectively; P=.09). Height-adjusted total kidney volume was also higher in the group without family history (P=.08).In MCIC classification, more patients in the non-family history group were classified 1C, 1D, and 1E than those in the group with family history of ADPKD (88.89% vs 70.14%, respectively); the opposite was true for MCIC 1A and 1B (11.11% vs 29.86%, respectively; P=.04). For patients without a clear family history of ADPKD, the ESRD prediction was 15.66 years versus 34.1 years for those with a clear family history of ADPKD (P=.025).In summary, the authors said, &ldquo;Patients with ADPKD without a clear family history tend to have more rapid progression and a worse renal prognosis than those with a clear family history of the same disease.&rdquo;Source: Gkika V, Louka M, Fokas S, et al. Patients with autosomal dominant polycystic kidney disease (ADPKD) without a clear family history have rapid progression and poor prognosis. Abstract of a presentation at the European Renal Association 59th Congress (M0008), Paris, France, May 19-22, 2022.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Progression and Prognosis in Patients With ADPKD Without Family History

ADPKD

Among patients with autosomal dominant polycystic kidney disease (ADPKD), a small percentage have no clear family history. This subgroup of patients may face a different ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe